Cargando…
Disparities by sex in P2Y(12) inhibitor therapy duration, or differences in the balance of ischaemic-benefit and bleeding-risk clinical outcomes in older women versus comparable men following acute myocardial infarction? A P2Y(12) inhibitor new user retrospective cohort analysis of US Medicare claims data
OBJECTIVES: To determine if comparable older women and men received different durations of P2Y(12) inhibitor therapy following acute myocardial infarction (AMI) and if therapy duration differences were justified by differences in ischaemic benefits and/or bleeding risks. DESIGN: Retrospective cohort...
Autores principales: | Hickson, Ryan P, Kucharska-Newton, Anna M, Rodgers, Jo E, Sleath, Betsy L, Fang, Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638457/ https://www.ncbi.nlm.nih.gov/pubmed/34853104 http://dx.doi.org/10.1136/bmjopen-2021-050236 |
Ejemplares similares
-
Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020
por: Essa, Mohammed, et al.
Publicado: (2023) -
P2Y12 inhibitors for the neurointerventionalist
por: Borchert, Robin J, et al.
Publicado: (2021) -
Real-World Bleeding and Ischemic Events in Asian Patients on P2Y12-Inhibitors After Percutaneous Coronary Intervention: A National Claims Data Analysis
por: Lee, Yonggu, et al.
Publicado: (2020) -
Aspirin and P2Y12 inhibitors in treating COVID-19
por: Khalaji, Amirmohammad, et al.
Publicado: (2023) -
Platelet CD40 ligand and bleeding during P2Y12 inhibitor treatment in acute coronary syndrome
por: Grosdidier, Charlotte, et al.
Publicado: (2019)